AMP-activated protein kinase and malonyl-CoA: Targets for treating insulin resistance?

Drug Discovery Today: Therapeutic Strategies

Volumn 2, Issue 2, 2005, Pages 157-163

  Ye, Ji Ming ^a   Ruderman, Neil B ^b   Kraegen, Edward W ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CERAMIDE; GLYCEROLIPID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; LIPID; MALONYL COENZYME A; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE;

ARTICLE; DISEASE MODEL; DRUG MECHANISM; DRUG TARGETING; DYSLIPIDEMIA; ENZYME ACTIVATION; ENZYME ACTIVITY; FATTY ACID OXIDATION; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LIVER; MUSCLE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; REGULATORY MECHANISM;

EID: 22144431872     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2005.05.019     Document Type: Review

References (52)

1. P. Zimmet et al. Global and societal implications of the diabetes epidemic Nature 414 2001 782-787
2. N.B. Ruderman et al. AMP kinase and malonyl-CoA: Targets for therapy of the metabolic syndrome Nat. Rev. Drug. Discov. 3 2004 340-351
3. N.B. Ruderman The Metabolic Syndrome. In De Groot and Jamieson: Endocrinology 5th edn 2005 Elsevier pp. 1149-1166
4. L.H. Storlien et al. Fish oil prevents insulin resistance induced by high-fat feeding in rats Science 237 1987 885-888
5. S.I. Itani et al. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha Diabetes 51 2002 2005-2011
6. J.M. Ye et al. Prior thiazolidinedione treatment preserves insulin sensitivity in normal rats during acute fatty acid elevation: Role of the liver Endocrinology 143 2002 4527-4535
7. D.R. Laybutt et al. Specific adaptations in muscle and adipose tissue in response to chronic systemic glucose oversupply in rats Am. J. Physiol. 273 1997 E1-E9
8. E.W. Kraegen et al. Insulin resistance induced by glucose infusion is associated temporally with reduced muscle and liver AMPK activity Diabetes 52 2003 A330
9. D.G. Hardie The AMP-activated protein kinase pathway - new players upstream and downstream J. Cell Sci. 117 2004 5479-5487
10. B.B. Kahn et al. AMP-activated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolism Cell Metab. 1 2005 15-25
11. R.R. Banerjee et al. Regulation of fasted blood glucose by resistin Science 303 2004 1195-1198
12. R. Barazzoni et al. Ghrelin regulates mitochondrial-lipid metabolism gene expression and tissue fat distribution in liver and skeletal muscle Am. J. Physiol. 288 2005 E228-E235
13. G. Zhou et al. Role of AMP-activated protein kinase in mechanism of metformin action J. Clin. Invest. 108 2001 1167-1174
14. H. Park et al. Coordinate regulation of malonyl-CoA decarboxylase, sn-glycerol-3-phosphate acyltransferase, and acetyl-CoA carboxylase by AMP-activated protein kinase in rat tissues in response to exercise J. Biol. Chem. 277 2002 32547-32571
15. C. Blazquez et al. The AMP-activated protein kinase prevents ceramide synthesis de novo and apoptosis in astrocytes FEBS Lett. 489 2001 149-153
16. J.M. Cacicedo et al. AMPK inhibits fatty acid-induced increases in NF-kappaB transactivation in cultured human umbilical vein endothelial cells Biochem. Biophys. Res. Commun. 324 2004 1204-1209
17. H. Zong et al. AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation Proc. Natl. Acad. Sci. USA 99 2002 15983-15987
18. M. Zhou et al. UCP-3 expression in skeletal muscle: Effects of exercise, hypoxia, and AMP-activated protein kinase Am. J. Physiol. 279 2000 E622-E629
19. S. Krauss et al. Superoxide-mediated activation of uncoupling protein 2 causes pancreatic beta cell dysfunction J. Clin. Invest. 112 2003 1831-1842
20. M.A. Stavinoha et al. Evidence for mitochondrial thioesterase 1 as a peroxisome proliferator-activated receptor-alpha-regulated gene in cardiac and skeletal muscle Am. J. Physiol. 287 2004 E888-E895
21. X. Yu et al. Leptinomimetic effects of the AMP kinase activator AICAR in leptin-resistant rats: Prevention of diabetes and ectopic lipid deposition Diabetologia 47 2004 2012-2021
22. A.K. Saha et al. Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo Biochem. Biophys. Res. Commun. 314 2004 580-585
23. M. Kelly et al. AMPK activity is diminished in tissues of IL-6 knockout mice: The effect of exercise Biochem. Biophys. Res. Commun. 320 2004 449-454
24. V. Wallenius et al. Interleukin-6-deficient mice develop mature-onset obesity Nat. Med. 8 2002 75-79
25. E.B. Taylor et al. Endurance training increases LKB1 and MO25 protein but not AMP-activated protein kinase kinase activity in skeletal muscle Am. J. Physiol. 287 2004 E1082-E1089
26. B. Viollet et al. The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity J. Clin. Invest. 111 2003 91-98
27. J. Mu et al. A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle Mol. Cell 7 2001 1085-1094
28. N. Musi et al. AMP-activated protein kinase (AMPK) is activated in muscle of subjects with type 2 diabetes during exercise Diabetes 50 2001 921-927
29. H.A. Koistinen et al. 5-Amino-imidazole carboxamide riboside increases glucose transport and cell-surface GLUT4 content in skeletal muscle from subjects with type 2 diabetes Diabetes 52 2003 1066-1072
30. N. Musi et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes Diabetes 51 2002 2074-2081
31. K. Hojlund et al. AMPK activity and isoform protein expression are similar in muscle of obese subjects with and without type 2 diabetes Am. J. Physiol. 286 2004 E239-E244
32. M.B. Chen et al. Impaired activation of AMP-kinase and fatty acid oxidation by globular adiponectin in cultured human skeletal muscle from obese type 2 diabetics J. Clin. Endocrinol. Metab. 90 2005 3665-3672
33. T. Kawaguchi et al. Mechanism for fatty acid "sparing" effect on glucose-induced transcription: Regulation of carbohydrate-responsive element-binding protein by AMP-activated protein kinase J. Biol. Chem. 277 2002 3829-3835
34. L.G. Fryer et al. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways J. Biol. Chem. 277 2002 25226-25232
35. M.E. Cleasby et al. Metformin prevents the development of acute lipid-induced insulin resistance in the rat through altered hepatic signaling mechanisms Diabetes 53 2004 3258-3266
36. M.A. Iglesias et al. AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats Diabetes 51 2002 2886-2894
37. V.A. Vaillancourt et al. Synthesis and biological activity of aminoguanidine and diaminoguanidine analogues of the antidiabetic/ antiobesity agent 3-guanidinopropionic acid J. Med. Chem. 44 2001 1231-1248
38. Y. Minokoshi et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase Nature 415 2002 339-343
39. T. Yamauchi et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase Nat. Med. 8 2002 1288-1295
40. K.F. Petersen et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy J. Clin. Invest. 109 2002 1345-1350
41. A. Xu et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice J. Clin. Invest. 112 2003 91-100
42. J. Fruebis et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice Proc. Natl. Acad. Sci. USA 98 2002 2005-2010
43. T. Pischon et al. Plasma adiponectin levels and risk of myocardial infarction in men J. Am. Med. Assoc. 291 2004 1730-1737
44. L. Abu-Elheiga et al. Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high-carbohydrate diets Proc. Natl. Acad. Sci. USA 100 2002 10207-10212
45. H.J. Harwood et al. Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals J. Biol. Chem. 278 2003 37099-37111
46. J. An et al. Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance Nat. Med. 10 2004 268-274
47. B.B. Yaspelkis et al. Leptin administration improves skeletal muscle insulin responsiveness in diet-induced insulin-resistant rats Am. J. Physiol. 280 2001 E130-E142
48. I. Shimomura et al. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy Nature 401 1999 73-76
49. T. Yamauchi et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity Nat. Med. 7 2002 941-946
50. J.M. Ye et al. Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: Comparison with metformin Diabetologia 47 2004 1306-1313
51. M. Tiikkainen et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes Diabetes 53 2004 2169-2176
52. B. Cool et al. Identification of a small molecule AMPK activator Diabetes 52 Suppl. 1 2003 A317